Wedbush Starts Oncothyreon (ONTY) at Outperform; Market is Undervaluing Assets
Tweet Send to a Friend
Wedbush initiates coverage on Oncothyreon (NASDAQ: ONTY) with a Outperform. PT $6.
Wedbush analyst says, "Oncothyreon and partner Merck KGAa ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "Oncothyreon and partner Merck KGAa ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
